Spec­trum floats new PhI­II idea af­ter FDA slaps down failed blad­der can­cer drug

Af­ter field­ing two failed Phase III stud­ies and watch­ing an FDA com­mit­tee vote unan­i­mous­ly against an ap­proval, you might say that to­day’s for­mal re­jec­tion of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER